NCT05027529

ECMOsorb Trial - Impact of a VA-ECMO in Combination With CytoSorb in Critically Ill Patients With Cardiogenic Shock

ECMOsorb Trial - Impact of a VA-ECMO in Combination With CytoSorb in Critically Ill Patients With Cardiogenic Shock- A Prospective, Randomized, Blinded, Monocenter Trial.

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 42 (actual)
• Sponsor: Christian Schulze · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

In the ECMOsorb study the impact of a veno-arterial -ECMO in combination with an extracorporeal cytokine hemadsorption system in critically ill patients with cardiogenic shock is to be examined

Detailed description

The prospective, interventional, randomised controlled and blinded ECMOsorb study investigates in critically ill patinets with cardiogenic shock and with veno-arterial ECMO (VA-ECMO) treatment the impact of an extracorporeal cytokin hemadsorption system on hemodynamics, defined by the Inotropic Score 72 hours after initiation of the adsorber (intervention) or normal ECMO tube (control) in the VA-ECMO.

Conditions

• Cardiogenic Shock

Interventions

Type	Name	Description
DEVICE	CytoSorb	An extracorporeal cytokine hemoadsorption system is integrated in the VA-ECMO circuit
OTHER	VA-ECMO only	only VA-ECMO; NO extracorporeal cytokine hemoadsorption system is added

Timeline

• Start date: 2021-05-21
• Primary completion: 2025-12-31
• Completion: 2025-12-31
• First posted: 2021-08-30
• Last updated: 2026-02-04

Locations

1 site across 1 country: Germany